Dirk Westermann

List of Publications by Year in Descending Order

101 papers	4,063 citations	31 h-index	62 g-index
120 ext. papers	5,575 ext. citations	7.8 avg, IF	5.26 L-index

#	Paper	IF	Citations
101	Percutaneous Transvalvular Microaxial Flow Pump Support in Cardiology.. *Circulation*, **2022**, 145, 1254-1264	28.7	0
100	Establishing a robotic-assisted PCI program: experiences at a large tertiary referral center.. *Heart and Vessels*, **2022**, 1	2.1	0
99	Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock: JACC Review Topic of the Week.. *Journal of the American College of Cardiology*, **2022**, 79, 1949-1962	15.1	1
98	Association Between the Acidemia, Lactic Acidosis, and Shock Severity With Outcomes in Patients With Cardiogenic Shock.. *Journal of the American Heart Association*, **2022**, 11, e024932	6	2
97	Performance of the European Society of Cardiology 0/1-Hour, 0/2-Hour, and 0/3-Hour Algorithms for Rapid Triage of Acute Myocardial Infarction : An International Collaborative Meta-analysis. *Annals of Internal Medicine*, **2021**,	8	5
96	Cardiac SARS-CoV-2 infection is associated with pro-inflammatory transcriptomic alterations within the heart. *Cardiovascular Research*, **2021**,	9.9	4
95	Sex differences in patients with cardiogenic shock. *ESC Heart Failure*, **2021**, 8, 1775-1783	3.7	3
94	cAMP Imaging at Ryanodine Receptors Reveals -Adrenoceptor Driven Arrhythmias. *Circulation Research*, **2021**, 129, 81-94	15.7	10
93	Response by Schrage and Westermann to Letters Regarding Article, "Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: Results From an International, Multicenter Cohort Study". *Circulation*, **2021**, 143, e1024	16.7	3
92	Prevention of coronary obstruction in patients at risk undergoing transcatheter aortic valve implantation: the Hamburg BASILICA experience. *Clinical Research in Cardiology*, **2021**, 110, 1900-1911	6.1	2
91	Lower socioeconomic status predicts higher mortality and morbidity in patients with heart failure. *Heart*, **2021**, 107, 229-236	5.1	8
90	Effects of COVID-19 on in-hospital cardiac arrest: incidence, causes, and outcome - a retrospective cohort study. *Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine*, **2021**, 29, 30	3.6	7
89	Health-related quality of life 1-3 years post-myocardial infarction: its impact on prognosis. *Open Heart*, **2021**, 8,	3	3
88	Temporal trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic shock. *ESC Heart Failure*, **2021**, 8, 1295-1303	3.7	9
87	Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials. *European Journal of Heart Failure*, **2021**, 23, 1942-1951	12.3	4
86	Seasonal trends of incidence and outcomes of cardiogenic shock : findings from a large, nationwide inpatients sample with 441,696 cases. *Critical Care*, **2021**, 25, 325	10.8	0
85	Influence of age and shock severity on short-term survival in patients with cardiogenic shock. *European Heart Journal: Acute Cardiovascular Care*, **2021**, 10, 604-612	4.3	12

84	Diabetes association with self-reported health, resource utilization, and prognosis post-myocardial infarction. *Clinical Cardiology*, **2020**, 43, 1352-1361	3.3	1
83	TAVR for low-flow, low-gradient aortic stenosis: Prognostic impact of aortic valve calcification. *American Heart Journal*, **2020**, 225, 138-148	4.9	3
82	Application of a machine learning-driven, multibiomarker panel for prediction of incident cardiovascular events in patients with suspected myocardial infarction. *Biomarkers in Medicine*, **2020**, 14, 775-784	2.3	1
81	Procedural volume and outcomes in patients undergoing VA-ECMO support. *Critical Care*, **2020**, 24, 291	10.8	8
80	High-Sensitivity Cardiac Troponin I Levels and Prediction of Heart Failure: Results From the BiomarCaRE Consortium. *JACC: Heart Failure*, **2020**, 8, 401-411	7.9	15
79	Temporal trends in incidence and outcome of acute coronary syndrome. *Clinical Research in Cardiology*, **2020**, 109, 1186-1192	6.1	24
78	Detailed interpretation of ECMO-ACCEPTS score. *Journal of Critical Care*, **2020**, 60, 327	4	
77	Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. *International Journal of Cardiology*, **2020**, 311, 7-14	3.2	4
76	Bridging INTERMACS 1 patients from VA-ECMO to LVAD via Impella 5.0: De-escalate and ambulate. *Journal of Critical Care*, **2020**, 57, 259-263	4	23
75	Application of the SCAI classification in a cohort of patients with cardiogenic shock. *Catheterization and Cardiovascular Interventions*, **2020**, 96, E213-E219	2.7	52
74	Patient Characteristics, Treatment and Outcome in Non-Ischemic vs. Ischemic Cardiogenic Shock. *Journal of Clinical Medicine*, **2020**, 9,	5.1	13
73	Switching to Impella 5.0 decreases need for transfusion in patients undergoing temporary mechanical circulatory support. *Journal of Critical Care*, **2020**, 57, 253-258	4	5
72	Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. *Clinical Cardiology*, **2020**, 43, 24-32	3.3	6
71	Risk prediction of in-hospital mortality in patients with venoarterial extracorporeal membrane oxygenation for cardiopulmonary support: The ECMO-ACCEPTS score. *Journal of Critical Care*, **2020**, 56, 100-105	4	12
70	Performance of the ESC 0/1-h and 0/3-h Algorithm for the Rapid Identification of Myocardial Infarction Without ST-Elevation in Patients With Diabetes. *Diabetes Care*, **2020**, 43, 460-467	14.6	8
69	Association of high-sensitivity troponin T and I with the severity of stable coronary artery disease in patients with chronic kidney disease. *Atherosclerosis*, **2020**, 313, 81-87	3.1	4
68	Epidemiology of intensive care unit cardiac arrest: Characteristics, comorbidities, and post-cardiac arrest organ failure - A prospective observational study. *Resuscitation*, **2020**, 156, 92-98	4	6
67	Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: Results From an International, Multicenter Cohort Study. *Circulation*, **2020**, 142, 2095-2106	16.7	83

66	Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. *JAMA Cardiology*, **2020**, 5, 1281-1285	16.2	371
65	Prevention and treatment of pulmonary congestion in patients undergoing venoarterial extracorporeal membrane oxygenation for cardiogenic shock. *European Heart Journal*, **2020**, 41, 3753-3761	9.5	26
64	Neuron-specific-enolase as a predictor of the neurologic outcome after cardiopulmonary resuscitation in patients on ECMO. *Resuscitation*, **2019**, 136, 14-20	4	17
63	Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry. *Circulation*, **2019**, 140, 1530-1539	16.7	41
62	Prognostic Value of a Novel and Established High-Sensitivity Troponin I Assay in Patients Presenting with Suspected Myocardial Infarction. *Biomolecules*, **2019**, 9,	5.9	6
61	Macrophage Migration Inhibitory Factor (MIF) Expression Increases during Myocardial Infarction and Supports Pro-Inflammatory Signaling in Cardiac Fibroblasts. *Biomolecules*, **2019**, 9,	5.9	10
60	Comparative Analysis of Circulating Noncoding RNAs Versus Protein Biomarkers in the Detection of Myocardial Injury. *Circulation Research*, **2019**, 125, 328-340	15.7	59
59	Cardiac glial cells release neurotrophic S100B upon catheter-based treatment of atrial fibrillation. *Science Translational Medicine*, **2019**, 11,	17.5	27
58	Relative Telomere Length and Cardiovascular Risk Factors. *Biomolecules*, **2019**, 9,	5.9	7
57	Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction. *Clinical Research in Cardiology*, **2019**, 108, 1386-1393	6.1	9
56	Impella 5.0 therapy as a bridge-to-decision option for patients on extracorporeal life support with unclear neurological outcomes. *European Journal of Cardio-thoracic Surgery*, **2019**, 56, 1031-1036	3	12
55	Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Addition to High-Sensitivity Troponin I in Early Diagnosis of Acute Myocardial Infarction. *Biomolecules*, **2019**, 9,	5.9	5
54	Reply: Does VA-ECMO Plus Impella Work in Refractory Cardiogenic Shock?. *JACC: Heart Failure*, **2019**, 7, 364-365	7.9	2
53	Hemodynamic Effects of Mechanical Circulatory Support Devices in Ventricular Septal Defect. *Circulation: Heart Failure*, **2019**, 12, e005981	7.6	31
52	Application of High-Sensitivity Troponin in Suspected Myocardial Infarction. *New England Journal of Medicine*, **2019**, 380, 2529-2540	59.2	134
51	Diagnostic Evaluation of a High-Sensitivity Troponin I Point-of-Care Assay. *Clinical Chemistry*, **2019**, 65, 1592-1601	5.5	23
50	Mechanical circulatory support devices in cardiogenic shock and acute heart failure: current evidence. *Current Opinion in Critical Care*, **2019**, 25, 391-396	3.5	9
49	Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock. *Circulation*, **2019**, 139, 1249-1258	16.7	213

48	Evaluation of a new ultra-sensitivity troponin I assay in patients with suspected myocardial infarction. *International Journal of Cardiology*, **2019**, 283, 35-40	3.2	9
47	Distinct Hemodynamic Changes After Interventional Mitral Valve Edge-to-Edge Repair in Different Phenotypes of Heart Failure: An Integrated Hemodynamic Analysis. *Journal of the American Heart Association*, **2018**, 7,	6	5
46	Indication and short-term clinical outcomes of high-risk percutaneous coronary intervention with microaxial Impella® pump: results from the German Impella® registry. *Clinical Research in Cardiology*, **2018**, 107, 653-657	6.1	24
45	De-escalation of support with veno-arterial extracorporeal membrane oxygenation and Impella for cardiogenic shock: reply. *European Journal of Heart Failure*, **2018**, 20, 622-623	12.3	
44	Prospective Validation of the 0/1-h Algorithm for Early Diagnosis of Myocardial Infarction. *Journal of the American College of Cardiology*, **2018**, 72, 620-632	15.1	82
43	Adverse Outcome Prediction of Iron Deficiency in Patients with Acute Coronary Syndrome. *Biomolecules*, **2018**, 8,	5.9	28
42	Diagnosing myocardial infarction: a highly sensitive issue. *Lancet, The*, **2018**, 392, 893-894	40	2
41	Unloading of the Left Ventricle During Venoarterial Extracorporeal Membrane Oxygenation Therapy in Cardiogenic Shock. *JACC: Heart Failure*, **2018**, 6, 1035-1043	7.9	66
40	Venoarterial Extracorporeal Membrane Oxygenation for Cardiopulmonary Support. *Circulation*, **2018**, 138, 2298-2300	16.7	52
39	Reply: Hospital Charges Associated With Inpatient Troponin Testing. *Journal of the American College of Cardiology*, **2018**, 72, 2941	15.1	
38	Precursor proadrenomedullin influences cardiomyocyte survival and local inflammation related to myocardial infarction. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E8727-E8736	11.5	14
37	Predictors of leptin concentration and association with cardiovascular risk in patients with coronary artery disease: results from the AtheroGene study. *Biomarkers*, **2017**, 22, 210-218	2.6	12
36	Challenging the 99th percentile: A lower troponin cutoff leads to low mortality of chest pain patients. *International Journal of Cardiology*, **2017**, 232, 289-293	3.2	21
35	High-sensitivity assays for troponin in patients with cardiac disease. *Nature Reviews Cardiology*, **2017**, 14, 472-483	14.8	94
34	Immediate Rule-Out of Acute Myocardial Infarction Using Electrocardiogram and Baseline High-Sensitivity Troponin I. *Clinical Chemistry*, **2017**, 63, 394-402	5.5	41
33	Cardiac Function Remains Impaired Despite Reversible Cardiac Remodeling after Acute Experimental Viral Myocarditis. *Journal of Immunology Research*, **2017**, 2017, 6590609	4.5	15
32	Early diagnosis of acute myocardial infarction using high-sensitivity troponin I. *PLoS ONE*, **2017**, 12, e0174288	3.7	16
31	Discrimination of patients with type 2 myocardial infarction. *European Heart Journal*, **2017**, 38, 3514-3520	9.5	63

30	Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome. *JAMA - Journal of the American Medical Association*, **2017**, 318, 1913-1924	27.4	117
29	Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction. *International Journal of Cardiology*, **2017**, 227, 272-277	3.2	42
28	Concomitant implantation of Impella on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. *European Journal of Heart Failure*, **2017**, 19, 404-412	12.3	265
27	Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study. *Clinical Cardiology*, **2017**, 40, 1197-1204	3.3	7
26	Radiation exposure during the implantation of bioabsorbable vascular scaffolds versus drug-eluting stents in non-complex coronary lesions: a matched-cohort study. *Minerva Cardiology and Angiology*, **2017**, 65, 1-7	2.4	
25	Diagnosis of Myocardial Infarction Using a High-Sensitivity Troponin I 1-Hour Algorithm. *JAMA Cardiology*, **2016**, 1, 397-404	16.2	125
24	SYNTAX score-0 patients: risk stratification in nonobstructive coronary artery disease. *Clinical Research in Cardiology*, **2016**, 105, 901-911	6.1	9
23	Cardiovascular Mortality in Chest Pain Patients: Comparison of Natriuretic Peptides With Novel Biomarkers of Cardiovascular Stress. *Canadian Journal of Cardiology*, **2016**, 32, 1470-1477	3.8	2
22	Risk factors for heart failure are associated with alterations of the LV end-diastolic pressure-volume relationship in non-heart failure individuals: data from a large-scale, population-based cohort. *European Heart Journal*, **2016**, 37, 1807-14	9.5	31
21	Activity of superoxide dismutase copper/zinc type and prognosis in a cohort of patients with coronary artery disease. *Biomarkers in Medicine*, **2015**, 9, 597-604	2.3	9
20	The utility of pregnancy-associated plasma protein A for determination of prognosis in a cohort of patients with coronary artery disease. *Biomarkers in Medicine*, **2015**, 9, 731-41	2.3	9
19	Risk Factors of Coronary Artery Disease in Secondary Prevention--Results from the AtheroGene--Study. *PLoS ONE*, **2015**, 10, e0131434	3.7	23
18	Cardiac fibroblasts support cardiac inflammation in heart failure. *Basic Research in Cardiology*, **2014**, 109, 428	11.8	96
17	Cardiac fibroblasts aggravate viral myocarditis: cell specific coxsackievirus B3 replication. *Mediators of Inflammation*, **2014**, 2014, 519528	4.3	31
16	Osteoglycin (OGN) modulates inflammation during viral myocarditis via an interaction with Toll Like Receptor 4.. *FASEB Journal*, **2013**, 27, 829.1	0.9	
15	Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. *Basic Research in Cardiology*, **2012**, 107, 308	11.8	47
14	The matricellular proteins thrombospondin-2, osteonectin and osteoglycin modulate cardiac inflammation, injury and function during viral myocarditis.. *FASEB Journal*, **2012**, 26, 1060.6	0.9	
13	Reduced degradation of the chemokine MCP-3 by matrix metalloproteinase-2 exacerbates myocardial inflammation in experimental viral cardiomyopathy. *Circulation*, **2011**, 124, 2082-93	16.7	67

12	Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. *Circulation: Heart Failure*, **2011**, 4, 44-52	7.6	371
11	Immunomodulation and matrix metalloproteinases in viral myocarditis. *Journal of Molecular and Cellular Cardiology*, **2010**, 48, 468-73	5.8	38
10	Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. *Diabetes*, **2009**, 58, 1373-81	0.9	84
9	Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure. *Basic Research in Cardiology*, **2009**, 104, 499-509	11.8	54
8	New perspective on the tissue kallikrein-kinin system in myocardial infarction: role of angiogenesis and cardiac regeneration. *International Immunopharmacology*, **2008**, 8, 148-54	5.8	22
7	Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor. *Biological Chemistry*, **2008**, 389, 713-8	4.5	19
6	Role of left ventricular stiffness in heart failure with normal ejection fraction. *Circulation*, **2008**, 117, 2051-60	16.7	327
5	Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. *Hypertension*, **2008**, 52, 1068-75	8.5	85
4	Renin inhibitors, clinical experience. *Journal of Molecular Medicine*, **2008**, 86, 691-5	5.5	15
3	Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. *Basic Research in Cardiology*, **2007**, 102, 500-7	11.8	151
2	Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy. *Diabetes*, **2007**, 56, 1834-41	0.9	114
1	Cardiac SARS-CoV-2 infection is associated with distinct transcriptomic changes within the heart		1